J. STANLEY HULL - Corporate Board Profile

PALATIN TECHNOLOGIES INC

Filing Date	Source Excerpt
2005-10-28	J. Stanley Hull has been a director since September 2005. Mr. Hull has nearly three decades of experience in the field of sales and marketing. Mr. Hull joined GlaxoSmithKline, a world leading research-based pharmaceutical company in October 1987 and is currently Senior Vice President for the US Pharmaceuticals 6 RTP Business Division. Prior to his current position, he served in the R&D organization of GlaxoSmithKline as Vice President and Worldwide Director of Therapeutic Development and Product Strategy-Neurology and Psychiatry. Prior to that, he was Vice President of Marketing 6 Infectious Diseases and Gastroenterology for Glaxo Wellcome Inc. Mr. Hull started his career in the pharmaceutical industry with SmithKline and French Laboratories in 1978. Mr. Hull received his B.S. in Business Administration from the University of North Carolina at Greensboro.
2006-10-30	J. Stanley Hull has been a director since September 2005. Mr. Hull has nearly three decades of experience in the field of sales and marketing. He is a director.
2007-10-29	J. Stanley Hull has been a director since September 2005. Mr. Hull has nearly three decades of experience in the field of sales and marketing.
2009-03-31	J. Stanley Hull has been a director since September 2005.
2010-04-07	J. Stanley Hull has been a director since September 2005. Mr. Hull has over three decades of experience in the field of sales and marketing. Mr. Hull joined GlaxoSmithKline, a research-based pharmaceutical company, in October 1987 and will retire as Senior Vice President, Pharmaceuticals in April 2010, having previously served in the R&D organization of GlaxoSmithKline as Vice President and Worldwide Director of Therapeutic Development and Product Strategy – Neurology and Psychiatry. Prior to that, he was Vice President of Marketing – Infectious Diseases and Gastroenterology for Glaxo Wellcome Inc. Mr. Hull started his career in the pharmaceutical industry with SmithKline and French Laboratories in 1978. Mr. Hull received his B.S. in business administration from the University of North Carolina at Greensboro.
2011-04-05	J. Stanley Hull has been a director since September 2005. ... Other non-employee directors receive an annual retainer of $30,000, payable on a quarterly basis.
2012-04-20	J. Stanley Hull has been a director since September 2005... Member of the Nominating and Corporate Governance Committee. Total compensation: $91,822.
2012-07-31	J. Stanley Hull listed as a director in the beneficial ownership table
2013-05-15	J. Stanley Hull has been a director since September 2005. He is a member of the nominating and corporate governance committee. For our 2012 fiscal year, Mr. Hull received an annual retainer of $32,000.
2014-05-06	J. Stanley Hull has been a director since September 2005... Member of the nominating and corporate governance committee... Director compensation table shows total compensation of $57,964.
2015-04-24	J. Stanley Hull has been a director since September 2005. ... Mr. Hull has extensive experience in commercial operations, development and marketing of pharmaceutical drugs and corporate alliances between pharmaceutical companies and biotechnology companies.
2016-04-22	J. Stanley Hull has been a director of Palatin since September 2005. ... (1) Member of the audit committee. (2) Member of the compensation committee. ... J. Stanley Hull received $45,000 in fees earned or paid in cash, $21,600 in stock awards, and $13,984 in option awards, totaling $80,584.
2017-04-28	J. Stanley Hull has been a director of Palatin since September 2005. Mr. Hull has over three decades of experience in the field of sales and marketing. Mr. Hull joined GlaxoSmithKline, a research-based pharmaceutical company, in October 1987 and retired as Senior Vice President, Pharmaceuticals in May 2010, having previously served in the R&D organization of Glaxo Wellcome as Vice President and Worldwide Director of Therapeutic Development and Product Strategy – Neurology and Psychiatry. Prior to that, he was Vice President of Marketing – Infectious Diseases and Gastroenterology for Glaxo Wellcome. Mr. Hull started his career in the pharmaceutical industry with SmithKline and French Laboratories in 1978. Mr. Hull received his B.S. in business administration from the University of North Carolina at Greensboro.
2018-05-17	J. STANLEY HULL has been a director of Palatin since September 2005... Audit committee includes Mr. Hull... Compensation committee includes Mr. Hull... Compensation table shows total compensation of $85,226.
2019-05-10	J. Stanley Hull has been a director of Palatin since September 2005. Mr. Hull has over three decades of experience in the field of sales, marketing and drug development. Mr. Hull joined GlaxoSmithKline, a research-based pharmaceutical company, in October 1987 and retired as Senior Vice President, Pharmaceuticals – North America in May 2010. Mr. Hull was responsible for all commercial activities including sales, marketing, sales training and office operations. Previously Mr. Hull served in the R&D organization of Glaxo Wellcome as Vice President and Worldwide Director of Therapeutic Development and Product Strategy – Neurology and Psychiatry. Prior to his service in the R&D organization he was Vice President of Marketing – Infectious Diseases and Gastroenterology for Glaxo Wellcome-U.S. Mr. Hull started his career in the pharmaceutical industry with SmithKline and French Laboratories in 1978. Mr. Hull received his B.S. in business administration from the University of North Carolina at Greensboro. Mr. Hull serves on the Audit Committee and the Compensation Committee. For fiscal 2018, Mr. Hull received total compensation of $142,775.
2020-05-11	J. Stanley Hull has been a director of Palatin since September 2005. He is a member of the audit committee and the compensation committee. For fiscal 2019, he received total compensation of $140,800.
2021-04-26	J. Stanley Hull has been a director of Palatin since September 2005... He is a member of the audit and compensation committees. Director compensation table shows total compensation of $142,200.
2022-05-24	J. Stanley Hull has been a director of Palatin since September 2005. (1) Member of the audit committee. (2) Member of the compensation committee. The following table sets forth the compensation we paid to all directors during fiscal 2021, except for Dr. Spana, whose compensation is set forth below in the Fiscal 2021 Summary Compensation Table and related disclosure. J. Stanley Hull 57,500 fees earned or paid in cash, 42,500 stock awards, 42,500 option awards, total 142,500.
2023-05-19	J. Stanley Hull has been a director of Palatin since September 2005. Mr. Hull has over three decades of experience in the field of sales, marketing, and drug development. Mr. Hull joined GlaxoSmithKline, a research-based pharmaceutical company, in October 1987 and retired as Senior Vice President, Pharmaceuticals – North America in May 2010. Mr. Hull was responsible for all commercial activities including sales, marketing, sales training, and office operations. Previously, Mr. Hull served in the R&D organization of Glaxo Wellcome as Vice President and Worldwide Director of Therapeutic Development and Product Strategy – Neurology and Psychiatry. Prior to his service in the R&D organization he was Vice President of Marketing – Infectious Diseases and Gastroenterology for Glaxo Wellcome-U.S. Mr. Hull started his career in the pharmaceutical industry with SmithKline and French Laboratories in 1978. Mr. Hull received his B.S. in business administration from the University of North Carolina at Greensboro. Mr. Hull has extensive experience in commercial operations, development, and marketing of pharmaceutical drugs and corporate alliances between pharmaceutical companies and biotechnology companies.
2024-05-28	J. Stanley Hull has been a director of Palatin since September 2005. He is a member of the audit committee and compensation committee. Compensation table shows total compensation of $102,466.